LOBE Lobe Sciences Ltd.

CNQ · CA · Healthcare · Biotechnology · lobesciences.com

0.0550CAD0.00%Mkt Cap: 12.34M $P/E: —3d ago

Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed t…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap12.34M USD

Enterprise Value9.76M USD

Revenue (TTM)—

Gross Profit0 USD

Net Income (TTM)-3.22M USD

Revenue/Share—

Last Price0.0550 CAD

Fiscal Year EndAug 2025

MR QuarterMay 2026

Employees—

CountryCA

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B7.86

EPS (TTM)-0.04

EPS (Forward)—

52W Range

0.030017% of range0.1800

52W High0.1800 CAD

52W Low0.0300 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-187.94%

ROA-58.34%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-1.03M USD

CapEx (TTM)—

FCF Margin—

FCF Yield-22.95%

Net Debt-3.55M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity0.12

Current Ratio2.38

Quick Ratio2.24

Book Value/Sh0.0070 CAD

Cash/Share0.02 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:6

Split DateJun 10, 2022

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.308.18M

Float126.94M

Insiders54.18%

Institutions0.00%

Short Interest

Short Ratio0.5d

Short % Out.0.02%

Shares Short21.35K

Short (prev mo.)3.50K

Technical

SMA 500.0780 (-29.5%)

SMA 2000.0808 (-31.9%)

Beta-0.01

S&P 52W Chg13.94%

Avg Vol (30d)67.94K

Avg Vol (10d)56.98K

Technical Indicators

RSI (14)31.3

MACD-0.0103

MACD Signal-0.0075

MACD Hist.-0.0028

BB Upper0.1130 CAD

BB Middle0.0813 CAD

BB Lower0.0495 CAD

BB Width78.20%

ATR (14)0.0100 CAD

Vol Ratio (20d)2.17x